NeoGuide's New Colonoscopy System Addresses ‘Looping'

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 3
Volume 15
Issue 3

NeoGuide Systems, Inc.'s computer-assisted colonoscopy system has received FDA 501(k) marketing clearance. The company's NeoGuide Endoscopy System is designed to eliminate the "looping" that may occur when the advancing endoscope displaces the colon and stretches the surrounding tissue.

LOS GATOS, California—NeoGuide Systems, Inc.'s computer-assisted colonoscopy system has received FDA 501(k) marketing clearance. The company's NeoGuide Endoscopy System is designed to eliminate the "looping" that may occur when the advancing endoscope displaces the colon and stretches the surrounding tissue. The system is built of multiple segments that can be actively controlled. As the NeoGuide scope is inserted, the system automatically creates a 3-D map of the colon and directs these segments to follow the path taken by the tip. Results of a clinical study will be reported at Digestive Disease Week 2006.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Treatment with KRAS inhibitors may help mitigate a common driver of genetic alteration across a majority of pancreatic cancers.
Updated results from the BREAKWATER study seemed to be most impactful to the CRC space, according to Michael J. Pishvaian, MD, PhD.
Future research will aim to assess the efficacy of PIPAC-MMC plus systemic therapy vs systemic therapy alone in patients with peritoneal tumors.
Although small incision surgery may serve as a conduit to deliver PIPAC-MMC, it may confer benefits in the staging and treatment of peritoneal tumors.
Patients with peritoneal metastases were historically associated with limited survival and low consideration for clinical trials.
Combining sotorasib with panitumumab may reduce the burden of disease in patients with KRAS G12C-mutated metastatic colorectal cancer.
Findings from the CodeBreak 300 study have cemented sotorasib/panitumumab as a third-line treatment option for KRAS G12C-mutated colorectal cancer.
Sotorasib plus panitumumab may offer improved survival compared with previously approved treatment options in KRAS G12C-mutated colorectal cancer.
Additional local, regional, or national policy may bolster access to screening for colorectal cancer, according to Aasma Shaukat, MD, MPH.
Related Content